Sandra Aung, Ph.D.
Affiliations: | 2000 | Vanderbilt University, Nashville, TN |
Area:
ImmunologyGoogle:
"Sandra Aung"Parents
Sign in to add mentor| Barney S. Graham | grad student | 2000 | Vanderbilt | |
| (Molecular mechanisms of CD8(+) T lymphocyte-induced cytotoxicity, interleukin-4, and respiratory syncytial virus pathogenesis.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Diab A, Tannir NM, Bentebibel SE, et al. (2020) Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). Cancer Discovery |
| Bentebibel SE, Hurwitz ME, Bernatchez C, et al. (2019) A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL-2-Receptor Beta/Gamma (βγ)-Biased Cytokine, in Patients With Advanced or Metastatic Solid Tumors. Cancer Discovery |
| van de Ven R, Hilton TL, Hu HM, et al. (2018) Autophagosome-based strategy to monitor apparent tumor-specific CD8 T cells in patients with prostate cancer. Oncoimmunology. 7: e1466766 |
| Vaena DA, Chaves J, Vogelzang NJ, et al. (2018) PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 36: TPS3115-TPS3115 |
| Sanborn RE, Ross HJ, Aung S, et al. (2017) A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer. Journal For Immunotherapy of Cancer. 5: 103 |
| Hurwitz ME, Diab A, Bernatchez C, et al. (2017) Effect of NKTR-214 on the number and activity of CD8+ tumor infiltrating lymphocytes in patients with advanced renal cell carcinoma. Journal of Clinical Oncology. 35: 454-454 |
| Diab A, Tannir NM, Bernatchez C, et al. (2017) A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors. Journal of Clinical Oncology. 35: e14040-e14040 |
| Bernatchez C, Haymaker CL, Hurwitz ME, et al. (2017) Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy. Journal of Clinical Oncology. 35: 2545-2545 |
| Buchbinder EI, Gunturi A, Perritt J, et al. (2016) A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. Journal For Immunotherapy of Cancer. 4: 52 |
| Clark J, Wong M, Daniels G, et al. (2015) Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2 F1000research. 6 |